Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma

NCT01794520 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT01794520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01794520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma
Lead sponsor
AbbVie
Phase
Phase 1/2
Overall status
Completed
Start date
October 10, 2012
Completion date
November 29, 2021
Enrollment
117 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma